The beginning of a new therapeutic era in acute myeloid leukemia
Abstract In the field of AML, the early 2000s were shaped by the advent of novel molecular biology technologies including high‐throughput sequencing that improved prognostic classification, response evaluation through the quantification of minimal residual disease, and the launch of research on targ...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-11-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.252 |
| _version_ | 1797740123122565120 |
|---|---|
| author | Christian Récher |
| author_facet | Christian Récher |
| author_sort | Christian Récher |
| collection | DOAJ |
| description | Abstract In the field of AML, the early 2000s were shaped by the advent of novel molecular biology technologies including high‐throughput sequencing that improved prognostic classification, response evaluation through the quantification of minimal residual disease, and the launch of research on targeted therapies. Our knowledge of leukemogenesis, AML genetic diversity, gene‐gene interactions, clonal evolution, and treatment response assessment has also greatly improved. New classifications based on chromosomal abnormalities and gene mutations are now integrated on a routine basis. These considerable efforts contributed to the discovery and development of promising drugs which specifically target gene mutations, apoptotic pathways and cell surface antigens as well as reformulate classical cytotoxic agents. In less than 2 years, nine novels drugs have been approved for the treatment of AML patients, and many others are being intensively investigated, in particular immune therapies. There are now numerous clinical research opportunities offered to clinicians, thanks to these new treatment options. We are only at the start of a new era which should see major disruptions in the way we understand, treat, and monitor patients with AML. |
| first_indexed | 2024-03-12T14:08:01Z |
| format | Article |
| id | doaj.art-ae0da44567f84bcd949c634bffe9d538 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-12T14:08:01Z |
| publishDate | 2021-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-ae0da44567f84bcd949c634bffe9d5382023-08-21T14:05:23ZengWileyeJHaem2688-61462021-11-012482383310.1002/jha2.252The beginning of a new therapeutic era in acute myeloid leukemiaChristian Récher0Service d'Hématologie Centre Hospitalier Universitaire de Toulouse Institut Universitaire du Cancer de Toulouse Oncopole Université Toulouse III Paul Sabatier Centre de Recherches en Cancérologie de Toulouse Toulouse FranceAbstract In the field of AML, the early 2000s were shaped by the advent of novel molecular biology technologies including high‐throughput sequencing that improved prognostic classification, response evaluation through the quantification of minimal residual disease, and the launch of research on targeted therapies. Our knowledge of leukemogenesis, AML genetic diversity, gene‐gene interactions, clonal evolution, and treatment response assessment has also greatly improved. New classifications based on chromosomal abnormalities and gene mutations are now integrated on a routine basis. These considerable efforts contributed to the discovery and development of promising drugs which specifically target gene mutations, apoptotic pathways and cell surface antigens as well as reformulate classical cytotoxic agents. In less than 2 years, nine novels drugs have been approved for the treatment of AML patients, and many others are being intensively investigated, in particular immune therapies. There are now numerous clinical research opportunities offered to clinicians, thanks to these new treatment options. We are only at the start of a new era which should see major disruptions in the way we understand, treat, and monitor patients with AML.https://doi.org/10.1002/jha2.252acute myeloid leukemiaCPX‐351enasidenibFLT3 inhibitorsgemtuzumab ozogamycingilteritinib |
| spellingShingle | Christian Récher The beginning of a new therapeutic era in acute myeloid leukemia eJHaem acute myeloid leukemia CPX‐351 enasidenib FLT3 inhibitors gemtuzumab ozogamycin gilteritinib |
| title | The beginning of a new therapeutic era in acute myeloid leukemia |
| title_full | The beginning of a new therapeutic era in acute myeloid leukemia |
| title_fullStr | The beginning of a new therapeutic era in acute myeloid leukemia |
| title_full_unstemmed | The beginning of a new therapeutic era in acute myeloid leukemia |
| title_short | The beginning of a new therapeutic era in acute myeloid leukemia |
| title_sort | beginning of a new therapeutic era in acute myeloid leukemia |
| topic | acute myeloid leukemia CPX‐351 enasidenib FLT3 inhibitors gemtuzumab ozogamycin gilteritinib |
| url | https://doi.org/10.1002/jha2.252 |
| work_keys_str_mv | AT christianrecher thebeginningofanewtherapeuticerainacutemyeloidleukemia AT christianrecher beginningofanewtherapeuticerainacutemyeloidleukemia |